Home › Companies › Anixa Biosciences, Inc. › 2025-2026
At Anixa Biosciences, Inc.'s shareholder meeting held March 10, 2026, in the 2025-2026 proxy season, 62 asset managers reported how they voted in their SEC Form N-PX filings, covering 140 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve on a non-binding, advisory basis the compensation of our named executive officers: — Anixa Biosciences, Inc.'s filing reports the proposal as approved, with 67% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Anixa Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on March 11, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Anixa Biosciences, Inc.’s Form 8-K, filed March 11, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of March 10, 2026: 6 items on Anixa Biosciences, Inc.’s Form 8-K, filed March 11, 2026: 2 approved · 4 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Anixa Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Anixa Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed March 11, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dr. Amit Kumar | 8,917,813 | -- | -- | 218,238 | 11,669,273 | 98% | Not verified | — |
| Elect Director: Dr. Arnold Baskies | 7,425,900 | -- | -- | 1,710,151 | 11,669,273 | 81% | Not verified | — |
| Elect Director: Emily Gottschalk | 7,249,290 | -- | -- | 1,886,761 | 11,669,273 | 79% | Not verified | — |
| Elect Director: Lewis H. Titterton, Jr. | 7,176,739 | -- | -- | 1,959,312 | 11,669,273 | 79% | Not verified | — |
| 2. Approval, by non-binding advisory vote, of the Company's executive compensation The Company's executive compensation, by non-binding advisory vote | 6,025,247 | 2,973,752 | 137,032 | -- | 11,669,273 | 67% | Approved | — |
| 3. Ratification of the appointment of independent registered public accounting firm The appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2026 | 20,426,524 | 191,432 | 187,368 | -- | -- | 99.0% | Approved | — |
Source: Anixa Biosciences, Inc., Form 8-K, filed with the SEC on March 11, 2026 — read the filing on EDGAR.
Each item below shows how the 62 asset managers that disclosed a Anixa Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Anixa Biosciences, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
100% of fund votes cast · no official result
Description as filed by funds: Election of Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. to hold office until the 2027 Annual Meeting of Stockholders or their successors are elected and qualified: Dr. Amit Kumar
The 4 asset managers below reported 1,444,086 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,260,341 | 0 | 0 | 0 | For |
| Fidelity | 174,436 | 0 | 0 | 0 | For |
| Equitable | 5,728 | 0 | 0 | 0 | For |
| Victory Capital | 3,581 | 0 | 0 | 0 | For |
99.7% of fund votes cast · no official result
Description as filed by funds: Election of Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. to hold office until the 2027 Annual Meeting of Stockholders or their successors are elected and qualified: Dr. Arnold Baskies
The 4 asset managers below reported 1,440,505 for, 3,581 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,260,341 | 0 | 0 | 0 | For |
| Fidelity | 174,436 | 0 | 0 | 0 | For |
| Equitable | 5,728 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 3,581 | Withhold |
99.7% of fund votes cast · no official result
Description as filed by funds: Election of Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. to hold office until the 2027 Annual Meeting of Stockholders or their successors are elected and qualified: Emily Gottschalk
The 4 asset managers below reported 1,440,505 for, 3,581 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,260,341 | 0 | 0 | 0 | For |
| Fidelity | 174,436 | 0 | 0 | 0 | For |
| Equitable | 5,728 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 3,581 | Withhold |
87% of fund votes cast · no official result
Description as filed by funds: Election of Dr. Amit Kumar, Dr. Arnold Baskies, Emily Gottschalk, and Lewis H. Titterton, Jr. to hold office until the 2027 Annual Meeting of Stockholders or their successors are elected and qualified: Lewis H. Titterton, Jr.
The 4 asset managers below reported 1,260,341 for, 183,745 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,260,341 | 0 | 0 | 0 | For |
| Fidelity | 0 | 0 | 0 | 174,436 | Withhold |
| Equitable | 0 | 0 | 0 | 5,728 | Withhold |
| Victory Capital | 0 | 0 | 0 | 3,581 | Withhold |
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: DIRECTOR: Dr. Amit Kumar
Anixa Biosciences, Inc.’s own tally for this item (“Elect Director: Dr. Amit Kumar”): 8,917,813 for, 218,238 withheld, per its Form 8-K filed March 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 18,671 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Charles Schwab | 12,785 | 0 | 0 | 0 | For |
| BlackRock | 5,022 | 0 | 0 | 0 | For |
| John Hancock | 864 | 0 | 0 | 0 | For |
Combines 2 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: DIRECTOR: Dr. Arnold Baskies
Anixa Biosciences, Inc.’s own tally for this item (“Elect Director: Dr. Arnold Baskies”): 7,425,900 for, 1,710,151 withheld, per its Form 8-K filed March 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 5,022 for, 12,785 withheld, 864 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Charles Schwab | 0 | 0 | 0 | 12,785 | Withhold |
| BlackRock | 5,022 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 864 | 0 | Abstain |
Combines 2 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: DIRECTOR: Emily Gottschalk
Anixa Biosciences, Inc.’s own tally for this item (“Elect Director: Emily Gottschalk”): 7,249,290 for, 1,886,761 withheld, per its Form 8-K filed March 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 5,022 for, 12,785 withheld, 864 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Charles Schwab | 0 | 0 | 0 | 12,785 | Withhold |
| BlackRock | 5,022 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 864 | 0 | Abstain |
Combines 2 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: DIRECTOR: Lewis H. Titterton, Jr.
Anixa Biosciences, Inc.’s own tally for this item (“Elect Director: Lewis H. Titterton, Jr.”): 7,176,739 for, 1,959,312 withheld, per its Form 8-K filed March 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 12,785 withheld, 5,886 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Charles Schwab | 0 | 0 | 0 | 12,785 | Withhold |
| BlackRock | 0 | 0 | 5,022 | 0 | Abstain |
| John Hancock | 0 | 0 | 864 | 0 | Abstain |
Combines 3 wordings of this item as funds reported it.
67% Approved · of votes cast
Description as filed by funds: To approve on a non-binding, advisory basis the compensation of our named executive officers:
Anixa Biosciences, Inc.’s own tally for this item (“2. Approval, by non-binding advisory vote, of the Company's executive compensation The Company's executive compensation, by non-binding advisory vote”): 6,025,247 for, 2,973,752 against — passed, per its Form 8-K filed March 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 - Approval, by non-binding advisory vote, of the Company's executive compensation The Company's executive compensation, by non-binding advisory vote, was approved.”
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,260,341 | 0 | 0 | 0 | For |
| Fidelity | 0 | 174,436 | 0 | 0 | Against |
| Charles Schwab | 0 | 12,785 | 0 | 0 | Against |
| Equitable | 5,728 | 0 | 0 | 0 | For |
| BlackRock | 5,022 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 3,581 | 0 | 0 | Against |
| John Hancock | 0 | 864 | 0 | 0 | Against |
Fund voting reports, all 7 managers: 1,271,091 for, 191,666 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Laird Norton Wetherby Trust Company, LLC | 0 | 586,027 | 0 | 0 | Against |
| D.A. DAVIDSON & CO. | 0 | 539,272 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 240,970 | 0 | 0 | Against |
| Vanguard | 159,303 | 119 | 0 | 0 | For |
| 683 Capital Management, LLC | 0 | 113,636 | 0 | 0 | Against |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 107,142 | 0 | 0 | Against |
| BlackRock | 89,779 | 0 | 0 | 0 | For |
| Newton Investment Management North America, LLC | 0 | 44,250 | 0 | 0 | Against |
| HighTower Advisors, LLC | 0 | 36,150 | 0 | 0 | Against |
| ACADIAN ASSET MANAGEMENT LLC | 0 | 34,539 | 0 | 0 | Against |
| Northern Trust | 0 | 28,421 | 0 | 0 | Against |
| Point72 | 0 | 26,910 | 0 | 0 | Against |
| CIBC Private Wealth Group LLC | 0 | 26,600 | 0 | 0 | Against |
| State Street | 22,184 | 213 | 0 | 0 | For |
| SEGALL BRYANT & HAMILL, LLC | 17,400 | 0 | 0 | 0 | For |
| KEYBANK NATIONAL ASSOCIATION/OH | 0 | 15,810 | 0 | 0 | Against |
| CANADA PENSION PLAN INVESTMENT BOARD | 0 | 13,500 | 0 | 0 | Against |
| Charles Schwab | 0 | 12,785 | 0 | 0 | Against |
| STALEY CAPITAL ADVISERS INC | 10,000 | 0 | 0 | 0 | For |
| Renaissance | 0 | 9,660 | 0 | 0 | Against |
| Sanctuary Advisors, LLC | 9,050 | 0 | 0 | 0 | For |
| BRADLEY FOSTER & SARGENT INC/CT | 8,544 | 0 | 0 | 0 | For |
| WELLS FARGO ADVISORS FINANCIAL NETWORK, LLC | 8,500 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 5,840 | 0 | 0 | 0 | For |
| Edward D. Jones & Co., L.P. | 0 | 3,830 | 0 | 0 | Against |
Institutional-manager reports, all 59 managers: 346,161 for, 1,868,391 against, 16 abstained. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.0% Approved · of votes cast
Description as filed by funds: To ratify the appointment by the Board of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2026:
Anixa Biosciences, Inc.’s own tally for this item (“3. Ratification of the appointment of independent registered public accounting firm The appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending October”): 20,426,524 for, 191,432 against — passed, per its Form 8-K filed March 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 - Ratification of the appointment of independent registered public accounting firm The appointment of Haskell & White LLP as the Company's independent registered public accounting firm for the fiscal year ending October 31, 2026 was ratified.”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 1,462,757 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,260,341 | 0 | 0 | 0 | For |
| Fidelity | 174,436 | 0 | 0 | 0 | For |
| Charles Schwab | 12,785 | 0 | 0 | 0 | For |
| Equitable | 5,728 | 0 | 0 | 0 | For |
| BlackRock | 5,022 | 0 | 0 | 0 | For |
| Victory Capital | 3,581 | 0 | 0 | 0 | For |
| John Hancock | 864 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 33,527,858 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.76% |
| 2 | Fidelity | 0.52% |
| 3 | Charles Schwab | 0.04% |
| 4 | Equitable | 0.02% |
| 5 | BlackRock | 0.01% |
| 6 | Victory Capital | 0.01% |
| 7 | John Hancock | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Laird Norton Wetherby Trust Company, LLC | 1.75% |
| 2 | D.A. DAVIDSON & CO. | 1.61% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 0.72% |
| 4 | Vanguard | 0.48% |
| 5 | 683 Capital Management, LLC | 0.34% |
| 6 | STIFEL NICOLAUS & CO INC \MO\ | 0.32% |
| 7 | BlackRock | 0.27% |
| 8 | Newton Investment Management North America, LLC | 0.13% |
| 9 | HighTower Advisors, LLC | 0.11% |
| 10 | ACADIAN ASSET MANAGEMENT LLC | 0.10% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Dr. Amit Kumar | 18.57% | DEF14A |
| Michael Catelani | 7.36% | 13D |
| Michael J. Catelani | 7.36% | DEF14A |
| Lewis H. Titterton, Jr. | 5.40% | DEF14A |
| Vanguard Group | 4.35% | 13F |
| Dr. Arnold Baskies | 1.47% | DEF14A |
| Geode Capital | 1.09% | 13F |
| Emily Gottschalk | 0.98% | DEF14A |
| BlackRock | 0.51% | 13F |
| State Street | 0.47% | 13F |
Percentages above are of 33,527,858 shares outstanding, as reported by Anixa Biosciences, Inc. on its Form 10-Q dated March 9, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Anixa Biosciences, Inc.’s 10-Q dated March 9, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Anixa Biosciences, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Anixa Biosciences (ANIX) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/anixa-biosciences-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.